Marcia Frellick ANAHEIM, California — A specially formulated toothpaste (INT301, Intrommune Therapeutics) met its safety endpoints as an oral immunotherapy to help adults with peanut allergy reduce their reaction risk, according to findings of a phase 1 study. The 48-week, randomized, double-blind, placebo-controlled trial enrolled 32 adults aged 18–55 with peanut allergy to receive in...